Screening for and validated quantification of amphetamines and of amphetamine‐ and piperazine‐derived designer drugs in human blood plasma by gas chromatography/mass spectrometry
- 16 June 2003
- journal article
- research article
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 38 (6) , 659-676
- https://doi.org/10.1002/jms.483
Abstract
The classical stimulants amphetamine, methamphetamine, ethylamphetamine and the amphetamine‐derived designer drugs MDA, MDMA (‘ecstasy’), MDEA, BDB and MBDB have been widely abused for a relatively long time. In recent years, a number of newer designer drugs have entered the illicit drug market. 4‐Methylthioamphetamine (MTA), p‐methoxyamphetamine (PMA) and p‐methoxymethamphetamine (PMMA) are also derived from amphetamine. Other designer drugs are derived from piperazine, such as benzylpiperazine (BZP), methylenedioxybenzylpiperazine (MDBP), trifluoromethylphenylpiperazine (TFMPP), m‐chlorophenylpiperazine (mCPP) and p‐methoxyphenylpiperazine (MeOPP). A number of severe or even fatal intoxications involving these newer substances, especially PMA, have been reported. This paper describes a method for screening for and simultaneous quantification of the above‐mentioned compounds and the metabolites p‐hydroxyamphetamine and p‐hydroxymethamphetamine (pholedrine) in human blood plasma. The analytes were analyzed by gas chromatography/mass spectrometry in the selected‐ion monitoring mode after mixed‐mode solid‐phase extraction (HCX) and derivatization with heptafluorobutyric anhydride. The method was fully validated according to international guidelines. It was linear from 5 to 1000 µg l−1 for all analytes. Data for accuracy and precision were within required limits with the exception of those for MDBP. The limit of quantification was 5 µg l−1 for all analytes. The applicability of the assay was proven by analysis of authentic plasma samples and of a certified reference sample. This procedure should also be suitable for confirmation of immunoassay results positive for amphetamines and/or designer drugs of the ecstasy type. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 74 references indexed in Scilit:
- Bioanalytical method validation and its implications for forensic and clinical toxicology - A reviewAccreditation and Quality Assurance, 2002
- RETRACTED: Severe Dopaminergic Neurotoxicity in Primates After a Common Recreational Dose Regimen of MDMA ("Ecstasy")Science, 2002
- Amphetamine-derived Designer Drugs: Metabolism and Screening ProceduresJournal of Laboratory Medicine, 2002
- Determination of paramethoxyamphetamine and other amphetamine-related designer drugs by liquid chromatography/sonic spray ionization mass spectrometryRapid Communications in Mass Spectrometry, 2002
- Tödliches Hirnödem nach Einnahme von Ecstasy und BenzylpiperazinDeutsche Medizinische Wochenschrift (1946), 2001
- Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (‘Ecstasy’)Toxicology Letters, 2000
- ILLEGAL OR LEGITIMATE USE? PRECURSOR COMPOUNDS TO AMPHETAMINE AND METHAMPHETAMINEDrug Metabolism Reviews, 2000
- Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxicationsAlimentary Pharmacology & Therapeutics, 1999
- Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamineArchives of Toxicology, 1992
- Effects of the pyrones, maltol and ethyl maltol, on iron absorption from the rat small intestineJournal of Pharmacy and Pharmacology, 1987